Clinical trial · Interventional
Preliminary Trial of SNA014 for Pancreatic Cancer
A Clinical Study on the Use of ⁶⁸Ga-labelled Claudin 18.2 as a Contrast Agent in Combination With PET/CT for the Imaging of Pancreatic Cancer
NCT07597772CI-TRIAL-00112048recruitingEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for pancreatic cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 68Ga-NODAGA-SNA006 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Group
- description
- 68Ga-NODAGA-SNA006
- interventionNames
- Drug: 68Ga-NODAGA-SNA006
Primary outcomes (4)
- measure
- The safety and tolerability profile of [68Ga]Ga-NODAGA-SNA014 in patients with CLDN18.2-positive pancreatic cancer.
- timeFrame
- 1 week
- description
- Occurrence of AE/SAE according to CTCAE 5.0
- measure
- CLDN18.2-targeting ability of [68Ga]Ga-NODAGA-SNA014 in patients with CLDN18.2-positive pancreatic cancer.
- timeFrame
- 1 week
- description
- SUVmax of tumors
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Aged between 18 and 75 years (inclusive); 2. Possessing legal capacity, voluntarily participating in this clinical trial, and having signed the informed consent form (ICF); 3. Patients with a confirmed diagnosis of pancreatic cancer whose tumours are suitable for Claudin-18.2 testing; 4. Results of gastroscopy, CT, MRI or PET-CT scans performed within the past month (if available); 5. Pathology test results from within the past year; Exclusion Criteria: 1. Patients with other clearly diagnosed malignant tumours; 2. Patients with uncontrolled severe infections, or those with other serious comorbidities; 3. Patients with a life expectancy of ≤3 months; 4. Pregnant or breastfeeding patients, and patients of childbearing potential who refuse to use appropriate contraception during the trial; 5. Patients deemed unsuitable for participation in this study by the investigator.
References
Publications (0)
Data not yet available
No reference posted for this study.